Factors affecting fistula failure in patients on chronic hemodialysis: a population–based case–control study

Cheng-Chieh Yen¹, Ching-Fang Tsai², Yueh-Yun Luo³, Hsin-Yi Yang², Mei-Yin Liu⁴, Peir-Haur Hung¹,⁵ and Yueh-Han Hsu¹,²,⁶,⁷*

Abstract

Background: With advancement of hemodialysis (HD) technique, late fistula failure (LFF) remains a problem significantly affecting life quality of patients. We attempt to identify factors affecting LFF in patients on chronic HD in Taiwan from the National Health Insurance Research Database.

Methods: This case–control study enrolled patients over 18 years old and who received regular HD for more than 3 months. LFF was defined as the first fistula failure episode beyond 3 months of chronic HD. We analyzed characteristics, comorbidities and medicine and investigated the association factors of LFF by logistic regression model. A trend test was conducted for risk in different provider levels. Sensitivity tests were conducted to test consistency.

Results: Of 1558 patients recruited, 772 (49.6%) were identified as LFF cases and 786 were identified as controls. The data showed that patients with diabetes mellitus (DM) had 42% increased rate of LFF. Patients receiving more than 10 HD sessions per month had a 90% increased rate of LFF; patients receiving chronic HD in private clinics had a 49% reduction rate of LFF. There were no significant differences in age, dialysis frequency, and comorbidities among different provider levels. There was a significant trend of risk reduction of the event from medical centers, regional hospitals, district hospitals, to private clinics. The sensitivity tests revealed similar results.

Conclusions: The factors associated with LFF include DM and receiving more HD sessions; on the contrary, receiving HD in private clinics is associated with less risk of LFF.

Keywords: Diabetes mellitus, Dialysis frequency, Dialysis provider level, Fistula care, Hemodialysis, Late fistula failure, Quality improvement, Taiwan

Background

For patients with end-stage renal disease (ESRD) receiving hemodialysis (HD), patency of vascular access is vital for maintenance of dialysis adequacy and quality of life. Access failure might prompt patients for urgent salvage interventions, threaten their lives by dialysis inadequacy [1], and increase financial burden of the healthcare system.

Literature has confirmed that fistula is the superior modality of vascular access [2], and prevalence of fistula use was reported ranging from 49 to 92% of dialysis-dependent patients around the world [3]. However, fistula failure remains a challenge to HD patients and nephrologists, with 51% to 60% of HD patients encountering fistula failure episodes [4]. Molecular mechanisms of fistula failure are complicated and still not well understood. The most acceptable hypothesis nowadays states that once fistula is created, thrombus, uremic toxins, shear stress, hypoxemia, and inflammation will alter expression
of endothelial genes and proteins, resulting in neointimal hyperplasia of fistula walls [5].

Late fistula failure (LFF), including stenosis and occlusion of fistula, is defined as failure episodes beyond 3 months after using fistula [6]. This condition contributes to the majority of failure events and is the leading cause of morbidities related to HD [7]. Numerous association factors with LFF were disclosed in the literature: Wood et al. revealed patients with old age and peripheral vascular disease (PVD) had higher risk of fistula failure [8]; Lok et al. reported male patients, patients with coronary artery disease and Caucasian ethnicity had significant fistula loss [9]. Smith et al. summarized factors affecting fistula patency, which included age, diabetes mellitus (DM), hypotension, vascular characters, smoking, ultrasound, surgical technique, and certain medicine [10]. However, the results are divergent relating to various study design and consider controversial at present.

Taiwan has become the country with the highest prevalence of ESRD [11] after implementation of the National Health Insurance (NHI) program in 1995. The ubiquitous coverage of NHI program provides integrated medical recording of registered participants. Given the divergent results of previous literature on LFF, we conducted a case-control study using the NHI Research Database (NHIRD) to identify factors affecting LFF in patients undergoing chronic HD in Taiwan.

Methods

Data source

We designed a population–based case–control study to investigate factors associated with LFF in patients undergoing chronic HD by means of the NHI program in Taiwan was launched on 1st March 1995. NHI coverage rate totaled 99.9% according to the National Health Insurance Annual Report in 2014 [12]. All identifications in the NHIRD were encrypted to ensure privacy of patients. We used the Longitudinal Health Insurance Database 2005 (LHID2005), a subset of NHIRD, which contained complete inpatient and ambulatory care claims for a random sample of 1 million beneficiaries enrolled in the year 2005 Registry for Beneficiaries. No significant difference was observed in distribution of sex, age, and average insured payroll-related amount between LHID2005 and the original NHIRD [13]. This study complied with the Declaration of Helsinki of World Medical Association in 2000 and was approved by the Institutional Review Board of Ditmanson Medical Foundation Chia-Yi Christian Hospital in Taiwan (CYCH–IRB No.106042). The informed consent was waived because of absence of interference of decision making processes related to patient care.

Study population

We recruited incident HD patients by using the NHI procedure codes of receiving HD from LHID2005 in 2000 and 2012. Chronic HD patients were defined as those receiving more than seven HD sessions monthly and HD regimen continued for at least 3 months. The enrollment was further restricted to those with arteriovenous fistula by using the NHI procedure codes of receiving fistula creation operation. Excluded patients comprised those aged less than 18 years, received peritoneal dialysis or kidney transplantation, or percutaneous transluminal angioplasty (PTA) before starting regular HD. Overall, the present study analyzed 1558 patients on chronic HD.

Identification of case and control groups

In our study, LFF was defined as the first fistula dysfunction episode, that required rescue treatments; beyond 3 months of chronic HD. Cases were identified as patients receiving the first episode of PTA or surgical reconstruction of permanent vascular access after a 3–month–chronic HD. PTA and surgeries were identified by using the corresponding NHI procedure codes. Controls comprised patients on chronic HD who did not receive PTA or surgical reconstructions. In total, we identified 772 cases and 786 controls in the present study, as shown in Fig. 1.

Definitions of comorbidities, medicine and other factors

We analyzed characteristics, comorbidities, and medication of study subjects. Age was classified into four categories of 18–44, 45–64, 65–84, and over 85 years old. Income was divided into three strata according to insurance fees: low (less than 20,000 New Taiwan Dollar [NTD] per month), intermediate (between 20,000 and 40,000 NTD per month), and high (more than 40,000 NTD per month). Urbanization levels were categorized into four levels, with level 1 was defined as the most urbanized and level 4 the least urbanized community, by adjustment of a population-based stratification study [14]. Dialysis frequency was stratified into two categories: one was less than 10 sessions per month, denoting twice or less HD a week; and the other was 10 sessions or more per month, denoting thrice HD a week. Provider level was defined as the facility where patients began receiving chronic HD. Comorbidities were defined as covariates, subjects experienced at least one hospitalization or two ambulatory visits within 1 year before starting HD due to any of the following illnesses: hypertension (HTN, International Classification of Diseases, 9th Revision, Clinical Modification [ICD–9–CM] code 401–405), ischemic heart disease (IHD, ICD–9–CM code 410–414), congestive heart failure (CHF, ICD–9–CM code 420.01, 420.11, 420.91, 425, 428, and 429.3), PVD (ICD–9–CM code 440–444, and 447), arrhythmia (ICD–9–CM code 426,427, V450, and V533), cerebrovascular accident (CVA, ICD–9–CM code 430–438), DM (ICD–9–CM code 250), hyperlipidemia (ICD–
9–CM code 272), hypotension (ICD–9–CM code 458), shock (ICD–9–CM code 785.5), and bloodstream–related infection (ICD–9–CM code 038, 041.9, 790.7). We also applied the Charlson comorbidity index (CCI) to denote burden of comorbidities [15]. Patients with DM were defined as DM with end organ damage [16]. We categorized CCI into three groups as scores 0–2, 3–4, and ≥ 5 according to tertiles of our data distribution. Medicine, including anticoagulants, antiplatelet agents, phosphodiesterase inhibitors, and statins, was defined as the prescription over 30 days per year within 1 year before starting HD. We also assessed midodrine, which was commonly prescribed for intradialytic hypotension, and defined it as the prescription over two times per year during HD vintage. As a sensitivity approach, we re-run the models and analyzed patients started chronic HD through their fistula without indwelling of non-tunneled or tunneled dialysis catheters.

Statistical analysis
Differences in patient characteristics, comorbidities, and medicine prescriptions were assessed by independent t-test and Chi-squared test. To investigate association factors of LFF in patients on chronic HD, we calculated the odds ratios (ORs) and 95% confidence intervals (CIs) by conducting logistic regression model. We also estimated the linear trend of hospital level of patients on chronic HD. All analyses were performed by operating the SPSS software for Windows (version 21.0; IBM Corporation, Somers, NY, USA). A two–tailed p value less than 0.05 was considered statistically significant.

Results
As shown in Table 1, 1,558 patients were enrolled in the study. A total of 772 (49.6%) patients experienced at least once LFF episode during their HD course, whereas 786 patients were free of LFF until termination of HD or the last day of 2012. Distributions of age (62.71 ± 13.22 years vs. 62.36 ± 13.45 years) and sex (female ratio: 49.35% vs. 44.66%) were similar between the LFF group and non–LFF group. A significantly higher percentage of LFF was observed among patients receiving more than 10 HD sessions per month (78.11% vs. 67.43%, p < 0.001). As to provider level of chronic HD, higher percentage of LFF was observed in medical centers (17.36% vs. 12.98%), regional hospitals (30.57% vs. 27.74%) and district hospitals (19.82% vs. 19.08%), but lower percentage of LFF was observed in private clinics (32.25% vs. 40.2%). CCI of LFF group and non-LFF group were similar (3.68 ± 2.43 vs. 3.86 ± 2.53, p = 0.152). No difference was detected in income, comorbidities, and medicine of patients between two groups.

To investigate the association factors of LFF in patients on chronic HD, we conducted logistic regression model, as shown in Fig. 2 (original data was shown in Additional file 1: Table S1). In multivariable analyses, there was a 49% reduced rate of LFF observed in patients in private clinics (OR: 0.51; 95% CI: 0.36–0.71) while a 90% increased rate in patients received more than 10 HD sessions per month (OR: 1.9; 95% CI: 1.49–2.40). Patients with DM presented a 42% higher rate of LFF than those without DM (OR: 1.42; 95% CI: 1.06–1.91). We did not find statistical association between LFF and other underlying characteristics, urbanization levels, CCI, and medicine.

As shown in Fig. 3, the trend test revealed a significant trend of risk reduction of LFF on provider levels of chronic HD (p < 0.001). We further performed stratification analysis, presented in Table 2, by means of provider level and disclosed no significant difference in age, sex,
| Table 1 Demographic characteristics of patients on chronic hemodialysis |
|---------------------------|-----------------|-----------------|-----------------|-----------------|
| Age, years                | Total (N = 1558) | LFF (N = 772)   | Non-LFF (N = 786) | p value         |
| 18–44                     | 162 (10.40)     | 74 (9.59)       | 88 (11.20)       | 0.677           |
| 45–64                     | 659 (42.30)     | 327 (42.36)     | 332 (42.24)      |                |
| 65–84                     | 708 (45.44)     | 358 (46.37)     | 350 (44.53)      |                |
| ≥85                       | 29 (1.86)       | 13 (1.68)       | 16 (2.04)        |                |
| Mean ± SD                 | 62.53 ± 13.34   | 62.71 ± 13.22   | 62.36 ± 13.45    | 0.601           |
| Sex                       |                 |                 |                 | 0.063           |
| Female                    | 732 (46.98)     | 381 (49.35)     | 351 (44.66)      |                |
| Male                      | 826 (53.02)     | 391 (50.65)     | 435 (55.34)      |                |
| Income, NTD per month     |                 |                 |                 | 0.485           |
| < 20,000                  | 1174 (75.35)    | 586 (75.91)     | 588 (74.81)      |                |
| 20,000–400,000            | 248 (15.92)     | 115 (14.90)     | 133 (16.92)      |                |
| ≥40,000                   | 136 (8.73)      | 71 (9.20)       | 65 (8.27)        |                |
| Urbanization              |                 |                 |                 | 0.048           |
| 1                         | 429 (27.71)     | 202 (26.34)     | 227 (29.07)      |                |
| 2                         | 808 (52.20)     | 427 (55.67)     | 381 (48.78)      |                |
| 3                         | 278 (17.96)     | 123 (16.04)     | 155 (19.85)      |                |
| 4                         | 33 (2.13)       | 15 (1.96)       | 18 (2.30)        |                |
| Provider level            |                 |                 |                 | 0.005           |
| Medical center            | 236 (15.15)     | 134 (17.36)     | 102 (12.98)      |                |
| Regional hospital         | 454 (29.14)     | 236 (30.57)     | 218 (27.74)      |                |
| District hospital         | 303 (19.45)     | 153 (19.82)     | 150 (19.08)      |                |
| Private clinic            | 565 (36.26)     | 249 (32.25)     | 316 (40.20)      |                |
| Dialysis frequency, per month |               |                 |                 | < 0.001        |
| < 10                      | 425 (27.28)     | 169 (21.89)     | 256 (32.57)      |                |
| ≥10                       | 1133 (72.72)    | 603 (78.11)     | 530 (67.43)      |                |
| CCI                       |                 |                 |                 | 0.415           |
| 0–2                       | 505 (32.41)     | 258 (33.42)     | 247 (31.42)      |                |
| 3–4                       | 532 (34.15)     | 268 (34.72)     | 264 (33.59)      |                |
| ≥5                        | 521 (33.44)     | 246 (31.87)     | 275 (34.99)      |                |
| Mean ± SD                 | 3.77 ± 2.48     | 3.68 ± 2.43     | 3.86 ± 2.53      | 0.152           |
| Comorbidity               |                 |                 |                 | 0.260           |
| Hypertension              | 1471 (94.42)    | 734 (95.08)     | 737 (93.77)      |                |
| Ischemic heart disease    | 701 (44.99)     | 343 (44.43)     | 358 (45.55)      | 0.658           |
| Congestive heart failure  | 640 (41.08)     | 306 (39.64)     | 334 (42.49)      | 0.252           |
| Peripheral vascular disease | 268 (17.20)   | 134 (17.36)     | 134 (17.05)      | 0.872           |
| Arteriovenous shunt       | 304 (19.51)     | 145 (18.78)     | 159 (20.23)      | 0.471           |
| Diabetes mellitus         | 955 (61.30)     | 489 (63.34)     | 466 (59.29)      | 0.100           |
| Hyperlipidemia            | 897 (57.57)     | 446 (57.77)     | 451 (57.38)      | 0.875           |
| Cerebrovascular accident  | 455 (29.20)     | 212 (27.46)     | 243 (30.92)      | 0.134           |
| Hypotension               | 60 (3.85)       | 29 (3.76)       | 31 (3.94)        | 0.848           |
| Shock                     | 50 (3.21)       | 24 (3.11)       | 26 (3.31)        | 0.824           |
| Bloodstream related infection | 301 (19.32)   | 141 (18.26)     | 160 (20.36)      | 0.299           |
or CCI among different provider levels. However, we observed that a significant higher percentage of HD patients receiving HD thrice weekly in private clinics (83.19%) than district hospitals (68.32%), regional hospitals (66.08%) and medical centers (66.10%, \( p < 0.001 \)). The results of sensitivity tests were similar to our main outcomes (as shown in Additional file 2: Figure S1 and Additional file 3: Table S2).

**Discussion**

In the present study, we observed that DM, dialysis frequency, and provider level of chronic HD affected risk of LFF. Diabetic patients showed a 42% increased rate of LFF. Patients who received more than 10 HD sessions per month featured a 90% increased rate of LFF. HD patients receiving regular HD at private clinics exhibited a 49% reduced rate of LFF than those who received HD in medical centers. A significant risk reduction of LFF was observed from medical centers, regional hospitals, district hospitals, and private clinics.

Endothelial dysfunction and increased thrombogenicity related to hyperglycemia affect patency of fistula and contribute DM as a risk factor of LFF [17]. Our results

| Drug use                  | Total (N = 1558) | LFF (N = 772) | Non-LFF (N = 786) | \( p \) value |
|---------------------------|------------------|---------------|-------------------|---------------|
| Anticoagulant             | 61 (3.92)        | 31 (4.02)     | 30 (3.82)         | 0.840         |
| Antiplatelet Agent        | 794 (50.96)      | 384 (49.74)   | 410 (52.16)       | 0.339         |
| Phosphodiesterase Inhibitor| 930 (59.69)     | 468 (60.62)   | 462 (58.78)       | 0.458         |
| Statin                    | 788 (50.58)      | 401 (51.94)   | 387 (49.24)       | 0.285         |
| Midodrine\(^a\)           | 83 (5.33)        | 40 (5.18)     | 43 (5.47)         | 0.799         |

\(^a\)Midodrine was used over 2 times per year during HD vintage

CCI Charlson comorbidity index, LFF late fistula failure, NTD new Taiwan dollar, SD standard deviation

**Table 1** Demographic characteristics of patients on chronic hemodialysis (Continued)

---

**Table 2** Sensitivity tests on multivariable analyses of late fistula failure of patients on chronic hemodialysis

---

**Fig. 2** Multivariable analyses of late fistula failure of patients on chronic hemodialysis. CCI: Charlson comorbidity index; CHF: congestive heart failure; CVA: cerebrovascular accident; DM: diabetes mellitus; HTN: hypertension; IHD: ischemic heart disease; LCL: lower confidence limit; LFF: late fistula failure; NTD: new Taiwan dollar; OR: odds ratio; PVD: peripheral vascular disease UCL: upper confidence limit
showed that LFF was more prevalent in diabetic patients. This result agreed with the findings from transnational studies [11, 18, 19]; though other study discovered that DM exerted no adverse effect on fistula complications [20]. The controversy might result from the difference of study subjects in terms of distribution of age and sex. Further investigation is warranted in consideration of vintage and severity (example: level of glycated hemoglobin) of DM for its divergent results on LFF.

Receiving over 10 HD sessions per month denotes administering thrice HD sessions per week. In our study, nearly three-fourths of patients received HD sessions thrice weekly, and they featured a 90% higher LFF rates than those who received HD sessions twice weekly. We made an internal validation by analyzing those without dialysis catheter indwelling before LFF. The effect of dialysis frequency showed more significant (OR: 2.3, 95% CI: 1.53–3.45) in subgroup analysis (Additional file 2: Figure S1). Dialysis frequency played a crucial role of dialysis adequacy, which influenced quality of life and mortality [21], and did not determine by the preference of nephrologists and patients. We observed that dialysis frequency might affect LFF due to the numbers of fistula usage. Increased dialysis frequency results in more significant risk of puncture mistake and hemostasis failure, which might cause LFF. Our finding was consistent with the research of Suri et al., which reported frequent HD raised the risk of vascular access complications [22].

As to the association between LFF and dialysis provider level, we observed that rate of LFF was significantly lower in private clinics in contrast to medical centers, regional hospitals, and district hospitals. Subgroup analysis of those without dialysis catheter indwelling was operated and exhibited similar results (OR: 0.57, 95% CI: 0.32–1.00, Additional file 2: Figure S1). Asano et al. compared treatment practices of dialysis facility from the Dialysis Outcomes and Practice Patterns Study (DOPPS) and concluded no significant association between fistula survival and physician and staff practices [23]. It might be limited since practices of physician and staff were defined by brief questionnaires and unquantifiable factors including education and nursing practice on fistula care, were not evaluated. We observed a 49% risk reduction of LFF in patients who received HD in private clinics after multivariable adjustment models (Fig. 2). In our study, patients in private clinics presented significantly higher ratio of receiving HD thrice weekly, with dialysis frequency analyzed as a factor of LFF. The burden of comorbidities, presented by CCI, was observed similar among different dialysis provider levels after validations (Table 2 and Additional file 3: Table S2). Taiwan Society of Nephrology has clearly regulated staffing of HD unit [24], though workload of HD facility was observed varied in different provider levels. We supposed that HD staff in private clinics might pay full attention to patient care, including fistula care and patient education, for example, rather than administrative loading. It might be a plausible cause of higher percentage of thrice–a–week in dialysis patients yet lower risk of LFF in private clinics.

Fistula care includes postoperative rehabilitation, physical examination, predialytic skin preparation, cannulation, intradialytic settings, critical management, hemostasis, and postdialytic surveillance. Guidelines and large–scale studies had confirmed that good quality of fistula care positively influenced survival of vascular access [25–28]. With regard to the association between LFF and fistula care factors, cannulation is a well-established factor. [29–31]. Additionally, literature ever reported that nursing staff affected LFF by their technique and education [24, 27, 32]. However, most factors outlined above were lack of objective definitions and quantifiable variables for investigation. Effect of dialysis frequency and dialysis provider level on LFF might imply direct and indirect evidence of fistula care, respectively.

We accessed the association between LFF and characteristics, comorbidities, and medicine of patients in the NHIRD. Our results showed that age was not a significant factor of LFF, agreeing with previous studies [19, 33]. Lazarides et al. observed that increased age might deteriorate LFF rate in a meta-analysis research; though only radiocephalic fistula was included [34]. We did not separate fistula location since radiocephalic fistula was not always the optimum choice for vascular access; thus our results might be more generalized to real world practice status. Our findings also showed no significant influence of sex on LFF, and were compatible with those of previous studies, including a meta-analysis article [33, 35].

As to comorbidities, PVD is another frequently-referred factor of LFF in addition to DM. Our results showed that HD patients with PVD featured a marginal risk excess of LFF than those without PVD (OR: 1.12, 95% CI: 0.85–1.48, Fig. 2), and this finding differed from those of previous
| Table 2: Characteristics of patients categorized by dialysis provider level |
|--------------------------------------------------|
| **Age, years** | Medical center \( (N = 236) \) | Regional hospital \( (N = 454) \) | District hospital \( (N = 303) \) | Private clinic \( (N = 565) \) | \( p \) value |
| 18–44 | 27 (11.44) | 43 (9.47) | 32 (10.56) | 60 (10.62) | 0.594 |
| 45–64 | 103 (43.64) | 207 (45.59) | 113 (37.29) | 236 (41.77) | 0.383 |
| 65–84 | 100 (42.37) | 198 (43.61) | 152 (50.17) | 258 (45.66) | 0.001 |
| ≥ 85 | 6 (2.54) | 6 (1.32) | 6 (1.98) | 11 (1.95) | 0.001 |
| **Mean ± SD** | 61.81 ± 14.37 | 62.12 ± 13.00 | 63.29 ± 13.07 | 62.76 ± 13.29 | 0.256 |
| **Sex** | | | | | |
| Female | 106 (44.92) | 215 (47.36) | 137 (45.21) | 274 (48.50) | 0.722 |
| Male | 130 (55.08) | 239 (52.64) | 166 (54.79) | 291 (51.50) | 0.722 |
| **Income** | | | | | |
| < 20,000 | 168 (71.19) | 352 (77.53) | 229 (75.58) | 425 (75.22) | 0.383 |
| 20,000–400,000 | 39 (16.53) | 71 (15.64) | 49 (16.17) | 89 (15.75) | < 0.001 |
| ≥ 40,000 | 29 (12.29) | 31 (6.83) | 25 (8.25) | 51 (9.03) | 0.001 |
| **Urbanization** | | | | | |
| 1 | 123 (52.12) | 84 (18.50) | 79 (26.42) | 143 (25.58) | < 0.001 |
| 2 | 113 (47.88) | 274 (60.35) | 128 (42.81) | 293 (52.42) | 0.001 |
| 3 | 0 (0.00) | 96 (21.15) | 77 (25.75) | 105 (18.78) | < 0.001 |
| 4 | 0 (0.00) | 0 (0.00) | 15 (5.02) | 18 (3.22) | < 0.001 |
| **Dialysis frequency, per month** | | | | | |
| < 10 | 80 (33.90) | 154 (33.92) | 96 (31.68) | 95 (16.81) | < 0.001 |
| ≥ 10 | 156 (66.10) | 300 (66.08) | 207 (68.32) | 470 (83.19) | 0.001 |
| **CCI** | | | | | |
| 0–2 | 87 (36.86) | 138 (30.40) | 85 (28.05) | 195 (34.51) | 0.220 |
| 3–4 | 74 (31.36) | 157 (34.58) | 105 (34.65) | 196 (34.69) | 0.001 |
| ≥ 5 | 75 (31.78) | 159 (35.02) | 113 (37.29) | 174 (30.80) | 0.001 |
| **Mean ± SD** | 3.66 ± 2.59 | 3.81 ± 2.39 | 4.01 ± 2.62 | 3.64 ± 2.42 | 0.001 |
| **Comorbidity** | | | | | |
| Hypertension | 217 (91.95) | 434 (95.59) | 290 (95.71) | 530 (93.81) | 0.152 |
| Ischemic heart disease | 100 (42.37) | 193 (42.51) | 155 (51.16) | 253 (44.78) | 0.092 |
| Congestive heart failure | 84 (35.59) | 201 (44.27) | 152 (50.17) | 203 (35.93) | < 0.001 |
| Peripheral vascular disease | 31 (13.14) | 58 (12.78) | 59 (19.47) | 120 (21.24) | 0.001 |
| Arrhythmia | 52 (22.03) | 86 (18.94) | 74 (24.42) | 92 (16.28) | 0.024 |
| Diabetes mellitus | 145 (61.44) | 283 (62.33) | 187 (61.72) | 340 (60.18) | 0.912 |
| Hyperlipidemia | 127 (53.81) | 259 (57.05) | 188 (62.05) | 323 (57.17) | 0.268 |
| Cerebrovascular disease | 54 (22.88) | 139 (30.62) | 106 (34.98) | 156 (27.61) | 0.014 |
| Hypotension | 9 (3.81) | 20 (4.41) | 14 (4.62) | 17 (3.01) | 0.584 |
| Shock | 5 (2.12) | 17 (3.74) | 15 (4.95) | 13 (2.30) | 0.123 |
| Bloodstream related infection | 44 (18.64) | 103 (22.69) | 57 (18.81) | 97 (17.17) | 0.165 |
| **Drug use** | | | | | |
| Anticoagulant | 6 (2.54) | 17 (3.74) | 18 (5.94) | 20 (3.54) | 0.192 |
| Antiplatelet Agent | 116 (49.15) | 228 (50.22) | 177 (58.42) | 273 (48.32) | 0.033 |
studies [36, 37]. Clinical presentations of PVD varied from absence of symptoms to critical ischemia. Our definition of PVD, which was based solely on the ICD–9–CM coding, might cause underestimation of diagnosis. Further validation tests are warranted for precise and inclusive definition of PVD.

We analyzed the medicine affecting vasculature, including anticoagulants, antiplatelet agents, phosphodiesterase inhibitors, and statins, in the NHIRD. Heparin was excluded owing to its widespread use during dialysis. Midodrine was included because of its common use for intradialytic hypotension and might represent occurrence of intradialytic hypotension, a remarkable risk factor of LFF [10]. Our results revealed none of them exerted significant influence on LFF, coinciding with the findings in DOPPS and other NHIRD studies [38, 39]. Cochrane systemic review by Tanner and Da Silva have revealed that ticlopidine might beneficially affect fistula patency [40]. Our study did not show similar results in subgroup analysis, and it might be related to small sample size of ticlopidine. In addition, Chang et al. have observed that statins might improve patency of fistula [41]. Our study did not show similar results, and it might be in relation to absence of medicine wash-out setting in our study design. Our study also failed to determine the association between LFF and midodrine, and it might refer to small sample number by our definition. Studies addressing the relationship between LFF and medicine as primary outcomes are required in the future.

We conducted a population–based study with 13–year–follow–up. The NHIRD allowed for obtaining data from the whole population in Taiwan related to its universal coverage regardless of socioeconomical status and physical condition. Characteristics of the NHIRD might reflect actual medical conditions in Taiwan. As shown in Fig. 1, we defined 3654 persons as chronic HD patients from the LHID2005, and it was comparable with epidemiological results of 2016 Annual Report on Kidney Disease in Taiwan published by the National Health Research Institutes [42]. In our study, rate of LFF reached 49.6%, which agreed with results of international multicenter studies [18, 43]. We strengthened definitions of comorbidities with ICD–9–CM codes for at least one hospitalization or two ambulatory visits to modify potential information bias in the NHIRD.

Our study faced several limitations. First, LFF was examined by clinical symptoms and image findings. However, those abnormalities were not available in forms of parameter in the NHIRD. Second, preoperative mapping, fistula location, vascular characters, surgical technique, first needling time, cannulation method, far infrared therapy, body mass index, and cigarette use were referred to important factors leading to LFF [10, 31] but lacking in our database. Third, our results might suppose the importance of fistula care and quality of care among different dialysis providers, but no proper surrogate has been developed for fistula care by far. Fourth, exposure to medicine was based on prescription information only. We could not determine whether patients adhered to prescribed schedule, and this condition might result in misclassification of exposure and underestimation of findings. Lastly, biomarkers such as calcium, phosphate, parathyroid hormone, C-reactive protein, and lipoproteins, were associated with LFF in previous studies [44, 45] but not available in the NHIRD. Integrated trials including laboratory data of study subjects should be conducted in the future to elucidate our results.

Conclusions
DM, dialysis frequency, and provider levels of chronic HD affected the risk of LFF. Diabetic patients featured a 42% increased rate of LFF. Patients with dialysis frequency of more than 10 HD sessions per month presented a 90% increased rate of LFF. Patients receiving chronic HD in private clinics showed a 49% reduction rate of LFF. A significant trend of risk reduction of LFF was observed from medical centers, regional hospitals, district hospitals, to private clinics. Dialysis frequency and provider level of chronic HD might imply linkage of LFF and fistula care. Quality of fistula care might be emphasized to reduce risk of LFF.

Additional files

Additional file 1: Table S1. Analysis of factors affecting late fistula failure in patients on chronic hemodialysis. (DOCX 17 kb)

Additional file 2: Figure S1. Multivariable analyses of late fistula failure of patients on chronic hemodialysis without dialysis catheter indwelling. CCI: Charlson comorbidity index; CHF: congestive heart failure; CVA: cerebrovascular accident; DM: diabetes mellitus; HTN: hypertension; IHD: ischemic heart disease; LCL: lower confidence limit; LFF: late fistula failure.
Abbreviations
CC: Charlson comorbidity index; CHF: Congestive heart failure; CI: Confidence interval; CVA: cerebrovascular accident; DM: Diabetes mellitus; DOPPS: Dialysis Outcomes and Practice Patterns Study; ESRD: End-stage renal disease; HD: Hemodialysis; HTN: Hypertension; ICD-9–CM: International Classification of Diseases, 9th Revision, Clinical Modification; IHD: Ischemic heart disease; LFF: Late fistula failure; LHID: Longitudinal Health Insurance Database; NHI: National Health Insurance; NHIRD: National Health Insurance Research Database; NTD: New Taiwan dollar; OR: Odds ratio; PTA: Percutaneous transluminal angioplasty; PVD: Peripheral vascular disease

Acknowledgements
We would like to thank Professor Chun-Ying Wu for his expert advice and encouragement throughout this study.

Availability of data and materials
The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
Research idea and study design: CCY, MYL, YHH; data acquisition: CFT; data analysis/interpretation: CCY, CFT, YYL, MYI, PHH, YHH; statistical analysis: CFT, HY; supervision of manuscript and revision process: CCY, YHH. Each author contributed important intellectual content during manuscript drafting or revision and accepted accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work were appropriately investigated and resolved. YHH took responsibility that this study has been reported honestly, accurately, and transparently; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Ditmanson Medical Foundation Chia-Yi Christian Hospital in Taiwan (CYCH–DIN–2018–06042). The informed consent was waived because of absence of interference of decision making processes related to patient care.

Consent for publication
Not applicable.

Competing interests
The authors declared that they had no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Division of Nephrology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, No.539, Zhongxiao Rd.60002, East Dist, Chia-Yi City, Taiwan. 2Department of Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi City, Taiwan. 3Health Center of Houbi District, Tainan City, Taiwan. 4Health Center of Houbi District, Tainan City, Taiwan. 5Department of Applied Life Science and Health, Chia–Nan University of Pharmacy and Science, Tainan City, Taiwan. 6Department of Medical Research, China Medical University Hospital, China Medical University, Taichung City, Taiwan. 7Department of Nursing, Min–Hweii College of Health Care Management, Tainan City, Taiwan.

References
1. Maiorca R, Brunori G, Zubani R, Cancarini GC, Manilli L, Gamberini C, Movilli E, Pola A, d’Avolio G, Gelatti U. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant. 1995;10(12):2295–305.
2. Ethier J, Mendessohn DC, Elder SJ, Haegewa T, Akizawa T, Akiba T, Canaud B, Pisoni RL. Vascular access use and outcomes: an international perspective from the Dialysis outcomes and practice patterns study. Nephrol Dial Transplant. 2008;23(10):3219–26.
3. Pisoni RL, Zepel L, Port FK, Robinson BM. Trends in US vascular access use, patient preferences, and related practices: an update from the US DOPPS practice monitor with international comparisons. Am J Kidney Dis. 2015;66(6):905–15.
4. Al-Jaishi AA, Oliver MJ, Thomas SM, Lok CE, Zhang JC, Garg AX, Kosa SD, Quinn RR, Moos LM. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2014;63(3):464–78.
5. Brahmhhart A, Remuzzi A, Franzoni M, Misra S. The molecular mechanisms of hemodialysis vascular access failure. Kidney Int. 2016;89(2):305–16.
6. Beathard GA, Arnold P, Jackson J, Litchfield T. Aggressive treatment of early fistula failure. Kidney Int. 2003;64(4):1487–94.
7. Mercado C, Salman I, Khithanamuthy G, Choi K, Artikov S, Thomas I, Merril D, Asif A. Early and late fistula failure. Clin Nephrol. 2008;69(2):77–83.
8. Woods JD, Turemne MN, Strawderman RL, Young EW, Hirth RA, Port FK, Held PJ. Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis. 1997;30(3):507–7.
9. Lok CE, Oliver MJ, Su J, Bhola C, Hannigan N, Jassal SV. Arteriovenous fistula outcomes in the era of the elderly dialysis population. Kidney Int. 2005;67(6):2462–9.
10. Smith GE, Gohil R, Chetter IC. Factors affecting the patency of arteriovenous fistulae for dialysis access. J Vasc Surg. 2012;55(3):69–9.
11. Robinson BM, Akizawa T, Lager KJ, Ker PG, Sarsani R, Pisoni RL. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet. 2016;388(10041):294–306.
12. National Health Insurance Administration MoHaW, Taiwan, ROC.: National Health Insurance Annual Report. 2014–2015. 2014;122.
13. Introduction to the National Health Insurance Research Database (NHIRD), Taiwan [http://nhird.nhri.org.tw/Date_01_en.html]. Accessed 1 Nov 2017.
14. Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS, Liang KY. Incorporating development stratification of Taiwan townships into sampling Design of Large Scale Health Interview Survey, J Health Manag. 2006;4(1):1–22.
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.
16. Wu PH, Lin YT, Lee TC, Lin MY, Kuo MC, Chiu YW, Hwang SJ, Chen HC. Predicting mortality of incident dialysis patients in Taiwan--a longitudinal population-based study. PLoS One. 2013;8(4):e61930.
17. Konner K. Primary vascular access in diabetic patients: an audit. Nephrol Dial Transplant. 2000;15(9):1317–25.
18. Huijbrechts HJ, Bots ML, Wittens CH, Schrama YC, Moll FL, Blankespin PJ, group Cs. Hemodialysis arteriovenous fistula patency revisited: results of a prospective, multicenter initiative. Clin J Am Soc Nephrol. 2008;3(3):714–9.
19. Fernstrom A, Hylander B, Olofsson P, Swedenborg J. Long and short term patency of radiocephalic arteriovenous fistulas. Acta Chir Scand. 1988;154(4):257–9.
20. Fokou M, Teyang A, Ashountang A, Kaze F, Eyengue VC, Chichom Mefire A, Angوكالة F 3rd. Complications of arteriovenous fistula for hemodialysis: an 8-year study. Ann Vasc Surg. 2012;26(5):680–4.
21. Oxen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993;329(14):1001–6.
22. Suri RS, Larive B, Sherer S, Eggers P, Gassman J, James SH, Lindsay RM, Lockridge RS, Ornitz DB, Rocco MV, et al. Risk of vascular access complications with frequent hemodialysis. J Am Soc Nephrol. 2013;24(3):498–505.
23. Asano M, Thurmna J, Oguchi K, Pisoni RL, Akizawa T, Akiba T, Fukushima S, Kurokawa K, Ethier J, Saran R, et al. Vascular access care and treatment
practices associated with outcomes of arteriovenous fistula: international comparisons from the Dialysis outcomes and practice patterns study. Nephron Clin Pract. 2013;124(1–2):23–30.

24. Liang YW, Huang LC, Yin YC, Chen WY, Chuang CL, Lee JL. Effect of nurse staffing on patient outcomes: a review of the literature. J Nurs. 2010;57(5):77–82.

25. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Clinical practice guidelines for vascular access. Am J Kidney Dis. 2006;48(Suppl 1):S176–247.

26. Navuluri R, Regalado S. The KDOQI. 2006 vascular access update and fistula first program synopsis. Semin Interv Radiol. 2009;26(2):122–4.

27. Murphy F. The ongoing challenges with renal vascular access. Br J Nurs. 2011;20(4):S6–14.

28. Parisotto MT, Schoeder VU, Muriunis C, Grassmann AH, Scatizzi LP, Kaufmann P, Stopper A, Marcelli D. Cannulation technique influences arteriovenous fistula and graft survival. Kidney Int. 2014;86(4):790–7.

29. Rayner KC, Pisoni RL, Gillespie BW, Goodkin DA, Akiba T, Akizawa T, Saito A, Young EW, Port FK. Creation, cannulation and survival of arteriovenous fistula: data from the Dialysis outcomes and practice patterns study. Kidney Int. 2003;63(1):323–30.

30. Saran R, Dykstra DM, Pisoni RL, Akiba T, Akizawa T, Canaud B, Chen K, Piera L, Saito A, Young EW. Timing of first cannulation and vascular access failure in haemodialysis: an analysis of practice patterns at dialysis facilities in the DOPPS. Nephrol Dial Transplant. 2004;19(9):2334–40.

31. van Loon MM, Goovaerts T, Kessels AG, van der Sande FM, Tordoir JH. Buttonhole needling of haemodialysis arteriovenous fistulae results in less complications and interventions compared to the rope-ladder technique. Nephrol Dial Transplant. 2010;25(1):225–30.

32. Banerjee S. Beyond needle placement: the role of the nephrology nurse in arteriovenous fistula management. Nephrol Nurs J. 2009;36(6):657–9.

33. Yaghoubian A, Lewis RJ, de Virgilio C. Can the National Kidney Foundation guidelines for first-time arteriovenous fistula creation be met in underserved end-stage renal disease patients? Ann Vasc Surg. 2008;22(1):5–10.

34. Lazarides MK, Georgiadis GS, Antoniou GA, Panagiotou S, Argyriou C, Mouvati E, Passadakis P, Lazarides MK. Correlation of pre-existing radial artery macrocalcifications with late patency of primary radiocephalic fistulas in diabetic hemodialysis patients. J Vasc Surg. 2007;45(2):420–6.

35. Roöjens PP, Tordoir JH, Stijnen T, Burgmans JP, de Smet AA, Ho YI. Radiocephalic wrist arteriovenous fistula for hemodialysis: meta-analysis indicates a high primary failure rate. Eur J Vasc Endovasc Surg. 2004;28(6):583–9.

36. Chan MR, Young HN, Becker YT, Yezziin AS. Obesity as a predictor of vascular access outcomes: analysis of the USRDS DMMS wave II study. Semin Dial. 2008;21(3):274–9.

37. Georgiadis GS, Georgakarakos EI, Antoniou GA, Panagiotou S, Argyriou C, Mouvati E, Passadakis P, Lazarides MK. Correlation of pre-existing radial artery macrocalcifications with late patency of primary radiocephalic fistulas in diabetic hemodialysis patients. J Vasc Surg. 2014;60(2):462–70.

38. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW, Dialysis O, Practice Patterns S. Association between vascular access failure and the use of specific drugs: the Dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2002;40(6):1255–63.

39. Kuo TH, Tseng CT, Lin WH, Chao JY, Wang WM, Li CY, Wang MC. Association between vascular access dysfunction and subsequent major adverse cardiovascular events in patients on hemodialysis: a population-based nested case-control study. Medicine (Baltimore). 2015;94(26):e1032.

40. Tanner NC, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 2015;7:CD002786.

41. Chang HH, Chang YK, Lu CW, Huang CT, Chien CT, Hung KY, Huang KC, Hsu CC. Statins improve long term patency of Arteriovenous fistula for hemodialysis. Sci Rep. 2016;6:22197.

42. Hsu CC, Hsung CA, Lu KC, Wu MS, Kao CC, Lin YC, et al. 2016 Annual report on kidney disease inTaiwan. Maoli County, Taiwan: National Health Research Institutes; 2017.

43. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol. 2006;17(4):112–27.

44. Otsson LF, Odellius R, Ribbe E, Hegbrant J. Evidence of calcium phosphate depositions in stenotic arteriovenous fistulas. Am J Kidney Dis. 2001;38(2):377–83.

45. Kaygın MA, Halici U, Aydin A, Dag O, Binici DN, Limandar HK, Arslan U, Kızılay A, Kahraman N, Canık E, et al. The relationship between arteriovenous fistula success and inflammation. Ren Fail. 2013;35(8):1085–8.